EGFR and non-small cell lung carcinoma: In the present study, therefore, we tested the combination of the EGFR inhibitor erlotinib and the PLK1 inhibitor volasertib in ER NSCLC models to determine the extent to which PLK1 inhibition overcomes EGFR TKI resistance.